Liminality as biographical disruption: unclassifiability following hormonal therapy for advanced prostate cancer

被引:76
|
作者
Navon, L [1 ]
Morag, A
机构
[1] Tel Aviv Univ, Sackler Fac Med, Sch Hlth Prof, Dept Nursing, IL-69978 Tel Aviv, Israel
[2] Chaim Sheba Med Ctr, Oncol Unit, IL-52621 Tel Hashomer, Israel
关键词
prostate cancer; hormonal therapy; liminality; biographical disruption; Israel;
D O I
10.1016/j.socscimed.2003.08.029
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The hormonal treatment of advanced prostate cancer involves life disruptive side-effects, such as impotence, libido loss and bodily feminisation. Conflicting views on the weight of the disruption they cause as against the therapy's survival benefits currently underlie debates over its appropriate mode of administration and its optimal timing in cases that do not necessitate immediate intervention. On the basis of a study of the disruptions caused to various life domains of 15 Israeli patients receiving such treatment, the present paper illustrates an integrated approach to their analysis that sheds new light on their intensity. The study was conducted by means of in-depth interviews and its data were processed according to the constant comparative analysis method. Its findings indicate that the therapy allowed the patients to regain their strength, to retain their need of love, basic masculine self-identification and spousal ties, and to renew their past social contacts. On the other hand they could no longer define themselves as healthy, sexually competent and 'male' in all respects, and their pre-treatment relationships with partners and friends lost the sense of closeness. Further psychosocial costs that were detected include patients' deprivation of their sense of continuity, excitements, hopes and coping capabilities. An integrated analysis of the concurrent normalisation and deviantisation processes undergone by them yielded the conclusion that the therapy subjects them to a liminal state, that is, the inability to classify themselves into culturally available categories. The difficulties entailed in this state highlight the need to take them into consideration when patients' condition allows a choice between alternative forms of hormonal therapy and between its early or deferred commencement. The interpretation of the disruption to their lives in terms of liminality also clarifies former studies' confusing reference to this subject and points to issues that still await investigation. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2337 / 2347
页数:11
相关论文
共 50 条
  • [31] BASIS FOR HORMONAL MANAGEMENT OF ADVANCED PROSTATE-CANCER
    GELLER, J
    CANCER, 1993, 71 (03) : 1039 - 1045
  • [32] Decreasing mortality rates for prostate cancer: possible role of hormonal therapy?
    Damber, JE
    BJU INTERNATIONAL, 2004, 93 (06) : 695 - 701
  • [33] Hormonal therapy and chemotherapy in patients with hormone-sensitive prostate cancer
    Gafanov, R. A.
    ONKOUROLOGIYA, 2016, 12 (01): : 63 - 68
  • [34] Role of hormonal therapy for prostate cancer: perspective from Japanese experiences
    Namiki, Mikio
    Ueno, Satoru
    Kitagawa, Yasuhide
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2012, 1 (03) : 160 - 172
  • [35] The side effects of hormonal therapy at the patients with prostate cancer
    Ziolkowska, Ewa
    Zarzycka, Malgorzata
    Wisniewski, Tomasz
    Zyromska, Agnieszka
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (06): : 491 - 497
  • [36] Addressing Cardiovascular Risk of Prostate Cancer Hormonal Therapy
    Ryan, Charles J.
    Morgans, Alicia K.
    JACC: CARDIOONCOLOGY, 2020, 2 (01): : 82 - 83
  • [37] Glucose intolerance during hormonal therapy for prostate cancer
    Suzuki, K.
    Nukui, A.
    Hara, Y.
    Morita, T.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2007, 10 (04) : 384 - 387
  • [38] First line indications for hormonal therapy in prostate cancer
    Boccon-Gibod, L.
    Richaud, P.
    Coloby, P.
    Coulange, C.
    Culine, S.
    Davin, J. -L.
    Soulie, M.
    Zerbib, M.
    PROGRES EN UROLOGIE, 2010, 20 (02): : 109 - 115
  • [39] Glucose intolerance during hormonal therapy for prostate cancer
    K Suzuki
    A Nukui
    Y Hara
    T Morita
    Prostate Cancer and Prostatic Diseases, 2007, 10 : 384 - 387
  • [40] Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: A retrospective multicenter study
    Ueno, Satoru
    Namiki, Mikio
    Fukagai, Takashi
    Ehara, Hidetoshi
    Usami, Michiyuki
    Akaza, Hideyuki
    INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (12) : 1494 - 1500